Arnon P Kater

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8708113/publications.pdf

Version: 2024-02-01

212	6,237	71102	82547
papers	citations	41 h-index	72 g-index

217	217	217	6882
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Venetoclaxâ€“Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2018, 378, 1107-1120.	27.0	684
2	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet, The, 2018, 391, 659-667.	13.7	324
3	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of Clinical Oncology, 2021, 39, 3441-3452.	1.6	266
4	miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood, 2009, 113, 3801-3808.	1.4	258
5	Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of Clinical Oncology, 2019, 37, 269-277.	1.6	250
6	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia, 2020, 34, 2354-2363.	7.2	198
7	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood, 2019, 133, 1205-1216.	1.4	164
8	Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood, 2007, 109, 1660-1668.	1.4	147
9	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. Journal of Clinical Oncology, 2020, 38, 4042-4054.	1.6	141
10	A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. Journal of Experimental Medicine, 2013, 210, 59-70.	8.5	132
11	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. Blood, 2019, 134, 44-58.	1.4	118
12	Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica, 2017, 102, 1629-1639.	3.5	111
13	Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia. Journal of Immunology, 2016, 197, 2532-2540.	0.8	110
14	c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood, 2008, 112, 5141-5149.	1.4	107
15	IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood, 2013, 122, 3010-3019.	1.4	107
16	Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica, 2015, 100, e302-6.	3.5	100
17	Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2012, 18, 487-498.	7.0	88
18	Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood, 2015, 125, 2306-2309.	1.4	79

#	Article	IF	Citations
19	Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Advances, 2019, 3, 2642-2652.	5.2	79
20	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood, 2021, 137, 1365-1376.	1.4	72
21	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood, 2016, 128, 574-583.	1.4	69
22	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia, 2019, 33, 2762-2766.	7.2	67
23	Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood, 2020, 136, 2918-2926.	1.4	67
24	Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. , 2022, 1, .		66
25	CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. British Journal of Haematology, 2004, 127, 404-415.	2.5	65
26	Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection. Journal of Hepatology, 2017, 66, 242-243.	3.7	65
27	B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18956-18960.	7.1	64
28	How does lenalidomide target the chronic lymphocytic leukemia microenvironment?. Blood, 2014, 124, 2184-2189.	1.4	60
29	Ibrutinibâ€associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and nonâ€Hodgkin lymphoma: An observational study. Mycoses, 2019, 62, 1140-1147.	4.0	57
30	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia, 2021, 35, 3444-3454.	7.2	57
31	Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood, 2005, 105, 3193-3198.	1.4	55
32	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, 2022, 140, 839-850.	1.4	55
33	CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. Blood, 2014, 123, 717-724.	1.4	53
34	In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow. Cancer Research, 2008, 68, 10137-10144.	0.9	52
35	Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. Haematologica, 2017, 102, 1469-1476.	3.5	52
36	Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood, 2011, 117, 6856-6865.	1.4	47

#	Article	IF	Citations
37	Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia. Haematologica, 2016, 101, e461-e464.	3.5	47
38	Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology,the, 2017, 4, e475-e486.	4.6	45
39	Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Advances, 2022, 6, 1537-1546.	5.2	45
40	Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematology,the, 2018, 5, e170-e180.	4.6	44
41	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia, 2019, 33, 390-402.	7.2	44
42	The Role of DNA and Actin Polymers on the Polymer Structure and Rheology of Cystic Fibrosis Sputum and Depolymerization by Gelsolin or Thymosin Beta 4. Annals of the New York Academy of Sciences, 2007, 1112, 140-153.	3.8	43
43	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. Haematologica, 2020, 106, 87-97.	3.5	43
44	Poor Outcomes of Chronic Active Epsteinâ€Barr Virus Infection and Hemophagocytic Lymphohistiocytosis in Nonâ€Japanese Adult Patients. Clinical Infectious Diseases, 2008, 47, 105-108.	5.8	42
45	Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. British Journal of Haematology, 2013, 163, 496-500.	2.5	42
46	Regulation of Bcl-XL by non-canonical NF-ÎºB in the context of CD40-induced drug resistance in CLL. Cell Death and Differentiation, 2021, 28, 1658-1668.	11.2	41
47	Improving CLL VÎ³9VÎ´2-Tâ€“cell fitness for cellular therapy by ex vivo activation and ibrutinib. Blood, 2018, 132, 2260-2272.	1.4	39
48	COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia, 2020, 34, 2225-2229.	7.2	39
49	A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. Blood, 2021, 138, 71-71.	1.4	36
50	DNA damageâ€“induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood, 2011, 117, 1622-1632.	1.4	35
51	Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?. Frontiers in Oncology, 2020, 10, 592205.	2.8	31
52	Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 1785-1794.	1.3	30
53	Cellular immune therapy for chronic lymphocytic leukemia. Blood, 2007, 110, 2811-2818.	1.4	29
54	A Bispecific Single-Domain Antibody Boosts Autologous VÎ³9VÎ´2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2021, 27, 1744-1755.	7.0	28

#	Article	IF	Citations
55	Thymosin Î²4 Sequesters Actin in Cystic Fibrosis Sputum and Decreases Sputum Cohesivity in Vitro. Chest, 2006, 130, 1433-1440.	0.8	27
56	Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia. Blood, 2021, 137, 1117-1120.	1.4	27
57	Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. Oncotarget, 2017, 8, 71981-71995.	1.8	27
58	Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study. Leukemia Research, 2014, 38, 34-41.	0.8	24
59	Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations. Expert Review of Hematology, 2018, 11, 613-624.	2.2	24
60	A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes VÎ³9VÎ´2 T cellâ€“Mediated Antitumor Responses in Human B-cell Malignancies. Cancer Immunology Research, 2021, 9, 50-61.	3.4	23
61	Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands. Blood, 2018, 131, 1380-1383.	1.4	22
62	Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. Blood Advances, 2018, 2, 3566-3571.	5.2	22
63	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Advances, 2022, 6, 4553-4557.	5.2	22
64	'Trained immunity: consequences for lymphoid malignancies. Haematologica, 2016, 101, 1460-1468.	3.5	21
65	Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences, 2019, 20, 4315.	4.1	21
66	Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 818-828.	10.7	21
67	Glucoseâ€6â€phosphate dehydrogenase deficiencyâ€associated hemolysis and methemoglobinemia in a <scp>COVID</scp>â€19 patient treated with chloroquine. American Journal of Hematology, 2020, 95, E194-E196.	4.1	20
68	Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia. Blood Advances, 2021, 5, 5410-5414.	5.2	20
69	First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study. Blood, 2021, 138, 70-70.	1.4	20
70	Dichotomal Effect of the Coumadin Derivative Warfarin on Inflammatory Signal Transduction. Vaccine Journal, 2002, 9, 1396-1397.	3.1	19
71	Final results of a phase 1b study of the safety and efficacy of the PI3KÎ´ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. Blood Cancer Journal, 2018, 8, 16.	6.2	19
72	CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. , 2020, 8, e000218.		19

#	Article	IF	Citations
73	T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. Haematologica, 2021, 106, 1234-1243.	3.5	18
74	Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Lancet Haematology,the, 2022, 9, e190-e199.	4.6	18
75	Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations. HemaSphere, 2022, 6, e707.	2.7	17
76	Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes. Journal of Immunology, 2019, 203, 2100-2109.	0.8	16
77	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 355-355.	1.4	16
78	EBV-Specific CD8+ T-Cells Are Not Functionally Impaired in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1723-1723.	1.4	16
79	Overview of available p53 function tests in relation toTP53andATMgene alterations and chemoresistance in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1849-1853.	1.3	15
80	The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. Frontiers in Oncology, 2020, 10, 609409.	2.8	15
81	Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study. Blood, 2020, 136, 44-45.	1.4	15
82	TP53 dysfunction in CLL: Implications for prognosis and treatment. Best Practice and Research in Clinical Haematology, 2016, 29, 90-99.	1.7	14
83	Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling. HemaSphere, 2019, 3, e308.	2.7	14
84	Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Blood, 2018, 132, 2876-2876.	1.4	14
85	Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Blood, 2017, 130, LBA-2-LBA-2.	1.4	14
86	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. Blood, 2022, 140, 630-643.	1.4	14
87	Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. British Journal of Haematology, 2004, 126, 512-516.	2.5	12
88	Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis. Leukemia and Lymphoma, 2012, 53, 2321-2325.	1.3	12
89	Venetoclaxâ€“Rituximab in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2018, 378, 2141-2144.	27.0	12
90	Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). Blood, 2016, 128, 229-229.	1.4	12

#	Article	IF	Citations
91	Sodium stibogluconate and CD47-SIRPÎ± blockade overcome resistance of anti-CD20â€“opsonized B cells to neutrophil killing. Blood Advances, 2022, 6, 2156-2166.	5.2	12
92	CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis. Haematologica, 2017, 102, 2069-2076.	3.5	11
93	Ibrutinib and Venetoclax for First-Line Treatment of CLL. New England Journal of Medicine, 2019, 381, 788-789.	27.0	11
94	Human CXCR5⁺PDâ€1⁺ CD8 T cells in healthy individuals and patients with hematologic malignancies. European Journal of Immunology, 2021, 51, 703-713.	2.9	11
95	Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Advances, 2021, 5, 913-925.	5.2	11
96	Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. Haematologica, 2019, 104, 147-154.	3.5	10
97	Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. Clinical Pharmacokinetics, 2019, 58, 1621-1634.	3.5	10
98	PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping. Blood, 2019, 134, 4304-4304.	1.4	10
99	Invasive infections with a coagulase-negative staphylococcus in an immunocompromised patient: case report and review of the literature. Annals of Hematology, 2008, 87, 771-772.	1.8	9
100	PD-L1 blockade: rejuvenating T cells in CLL. Blood, 2015, 126, 126-128.	1.4	9
101	Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers, 2020, 12, 3837.	3.7	9
102	A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation. Blood, 2019, 134, 4318-4318.	1.4	9
103	Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?. Hematology/Oncology Clinics of North America, 2021, 35, 775-791.	2.2	8
104	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 184-184.	1.4	8
105	Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma. Leukemia, 2022, 36, 2165-2176.	7.2	8
106	Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 115-20.	2.3	7
107	Assessment of <scp>TP</scp>53 functionality in chronic lymphocytic leukaemia by different assays; an <scp>ERIC</scp>â€wide approach. British Journal of Haematology, 2014, 167, 565-569.	2.5	7
108	Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 52-57.	0.4	7

#	Article	IF	Citations
109	Exposureâ€“response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. Leukemia and Lymphoma, 2020, 61, 56-65.	1.3	7
110	Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance â‰¥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations. BMJ Open, 2020, 10, e039168.	1.9	7
111	Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies. Blood, 2013, 122, 2881-2881.	1.4	7
112	The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2018, 36, TPS7582-TPS7582.	1.6	7
113	Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 2439-2447.	1.3	6
114	Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA. Haematologica, 2016, 101, e374-e377.	3.5	6
115	Ibrutinib: searching for a partner drug. Lancet Oncology, The, 2019, 20, 3-5.	10.7	6
116	CAR-T and ibrutinib vs CLL: sequential or simultaneous?. Blood, 2020, 135, 1611-1612.	1.4	6
117	Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab. Haematologica, 2020, 105, e382-e383.	3.5	6
118	Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL â€“ The Role Of Abl and Btk. Blood, 2013, 122, 4188-4188.	1.4	6
119	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. Journal of Clinical Oncology, 2018, 36, TPS7588-TPS7588.	1.6	6
120	Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial. Blood, 2021, 138, 2627-2627.	1.4	6
121	Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989â€“2018. Blood Cancer Journal, 2022, 12, 72.	6.2	6
122	Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas. Cancer Research Communications, 2022, 2, 330-341.	1.7	6
123	Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells. Blood Advances, 2022, 6, 4185-4195.	5.2	6
124	The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia. Leukemia Research, 2013, 37, 838-847.	0.8	5
125	Rare but Serious: Ibrutinib Induced Liver Failure. HemaSphere, 2019, 3, e307.	2.7	5
126	First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment. Blood, 2018, 132, 1860-1860.	1.4	5

#	Article	IF	Citations
127	SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy. Blood, 2012, 120, 711-711.	1.4	5
128	Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx). Blood, 2021, 138, 1548-1548.	1.4	5
129	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study. Blood, 2020, 136, 38-39.	1.4	5
130	Waxing and waning intravascular large cell lymphoma with widespread organ infiltration. Leukemia and Lymphoma, 2011, 52, 705-708.	1.3	4
131	Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R) Tj ETQq1 1 0.784314 rgBT /Overl HO141 Trial. Blood, 2019, 134, 4292-4292.	1.4	4
132	Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features. Frontiers in Oncology, 2021, 11, 780085.	2.8	4
133	Functional Differences Between EBVâ€•and CMVâ€Specific CD8⁺ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL. HemaSphere, 2020, 4, e337.	2.7	3
134	Combined Inhibition of mTOR and DNA-PK Blocks Survival, Adhesion, Proliferation and Chemoresistance in Primary Chronic Lymphocytic Leukemia (CLL) Cells. Blood, 2014, 124, 1981-1981.	1.4	3
135	The T-Cell/CLL/Macrophage Triad Shapes a Supportive Tumor Microenvironment in CLL. Blood, 2015, 126, 1715-1715.	1.4	3
136	Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to Î³Î´-T Cell Mediated Killing, Provided CLL-Derived Î³Î´-T Cell Dysfunction Can be Reversed. Blood, 2015, 126, 2914-2914.	1.4	3
137	Bcl-2 Members As Drug Target and Biomarkers for Response to Ibrutinib and Venetoclax in CLL. Blood, 2016, 128, 2043-2043.	1.4	3
138	Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD - Primary Analysis from the Randomized Phase II Vision HO141 Trial. Blood, 2021, 138, 69-69.	1.4	3
139	High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial. Blood, 2021, 138, 72-72.	1.4	3
140	Ibrutinib Treatment in CLL Interrupts CD40 Signaling Capacity and Sensitizes CLL Cells to Venetoclax. Blood, 2021, 138, 1545-1545.	1.4	3
141	Conditional relative survival among patients with chronic lymphocytic leukaemia: A populationâ€based study in the Netherlands. EJHaem, 2022, 3, 180-183.	1.0	3
142	T-cell subset composition and functionality in patients with WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia and Lymphoma, 2022, , 1-5.	1.3	3
143	Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110. Leukemia, 2022, , .	7.2	3
144	Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. Leukemia and Lymphoma, 2022, 63, 2276-2289.	1.3	3

#	Article	IF	Citations
145	Standards for the Treatment of Relapsed Chronic Lymphocytic Leukemia: A Case-Based Study. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S34-S41.	0.4	2
146	Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study. Experimental Hematology, 2020, 89, 55-60.e6.	0.4	2
147	Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy. Blood, 2018, 132, 235-235.	1.4	2
148	First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Blood, 2018, 132, 185-185.	1.4	2
149	Combined Ibrutinib and Venetoclax Changes Myeloid Phenotype and Improves Immune Function in CLL Patients. Blood, 2019, 134, 4289-4289.	1.4	2
150	First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial). Blood, 2019, 134, 1753-1753.	1.4	2
151	c-Abl Kinase Inhibitors Overcome CD40-Mediated Drug Resistance in CLL.. Blood, 2007, 110, 3078-3078.	1.4	2
152	Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). Blood, 2014, 124, 4699-4699.	1.4	2
153	Mapping the Targets of Dasatinib in Chronic Lymphocytic Leukemia Reveals Distinct Roles for Abl and Btk in Drug Resistance and Adhesion, and Explains Clinical Effects On Lymph Node Reduction. Blood, 2012, 120, 3900-3900.	1.4	2
154	A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. Blood, 2014, 124, 1976-1976.	1.4	2
155	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. Blood, 2020, 136, 45-49.	1.4	2
156	Increasing CART cell engine performance in CLL. Blood, 2022, 139, 473-474.	1.4	2
157	A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies. EJHaem, 2022, 3, 492-506.	1.0	2
158	The 8th Young Investigatorsâ€™ Meeting on Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2015, 56, 1556-1559.	1.3	1
159	Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy. Leukemia and Lymphoma, 2018, 59, 2757-2761.	1.3	1
160	Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib. Leukemia and Lymphoma, 2020, 61, 3422-3431.	1.3	1
161	Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial. Blood, 2019, 134, 356-356.	1.4	1
162	CD40-Activation of Chronic Lymphocytic Leukemia Cells Induces Latent Sensitivity to Fas/TRAIL-Mediated Apoptosis Via a P53-Independent, C-Abl-Dependent Pathway.. Blood, 2004, 104, 342-342.	1.4	1

#	Article	IF	Citations
163	Inhibition of XIAP Enhances Specific Cytotoxic T Lymphocyte (CTL) Killing and CD20-Directed Antibody-Dependent Cellular Cytotoxicity of Chronic Lymphocytic Leukemia B Cells.. Blood, 2004, 104, 3475-3475.	1.4	1
164	Assessment of p53 Functionality in Chronic Lymphocytic Leukemia by Different Assays; An Eric-Wide Approach.. Blood, 2012, 120, 2872-2872.	1.4	1
165	The Impact Of Subclonal Versus Clonal Novel Recurrent Mutations On Treatment Outcome In Previously Untreated High Risk CLL Patients: Results From The HOVON68 Trial. Blood, 2013, 122, 2861-2861.	1.4	1
166	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. Blood, 2016, 128, 4376-4376.	1.4	1
167	Mir-34a as Part of the Chemotherapy Resistance Network in Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 1209-1209.	1.4	1
168	B Cell Activating Factor and c-Myc Regulate the Progression of Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 359-359.	1.4	1
169	Identification of a Novel B-CLL Subset Expressing Mutated Stereotyped B-Cell Receptors with Specificity for Yeast Mannan. Blood, 2011, 118, 623-623.	1.4	1
170	The Broad Kinase Inhibitor Dasatinib in Combination with Fludarabine in Patients with Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase 2 Study. Blood, 2012, 120, 1798-1798.	1.4	1
171	Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform Î± and Î´ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation. Blood, 2014, 124, 4691-4691.	1.4	1
172	Impaired Metabolic Fitness in T Cells in Chronic Lymphocytic Leukemia. Blood, 2016, 128, 2528-2528.	1.4	1
173	Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia. Blood, 2019, 134, 479-479.	1.4	1
174	Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial. Blood, 2021, 138, 2639-2639.	1.4	1
175	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. Blood, 2021, 138, 2635-2635.	1.4	1
176	Chronic Lymphocytic Leukemia Actively Induces T-Cell Dysfunction By Contact-Dependent Signaling Via CD24 and CD52. Blood, 2021, 138, 3714-3714.	1.4	1
177	Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia. Blood, 2020, 136, 36-37.	1.4	1
178	Do CARs finally hit the CLL road?. Blood, 2022, 139, 1775-1776.	1.4	1
179	Highlights of the 6th Young Investigatorsâ€™ Meeting on chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 2312-2313.	1.3	0
180	miR in CLL: more than mere markers of prognosis?. Blood, 2014, 124, 2-4.	1.4	0

#	Article	IF	Citations
181	Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?. HemaSphere, 2019, 3, 44-46.	2.7	0
182	Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia. Annals of Hematology, 2020, 99, 1081-1091.	1.8	0
183	Poster: CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S220.	0.4	0
184	Inhibition of XIAP Renders Newly CD40-Activated Chronic Lymphocytic Leukemia Cells Sensitive to Fas (CD95) Mediated Apoptosis.. Blood, 2004, 104, 3474-3474.	1.4	0
185	Autologous CMV-Specific T Cells as Effector Cells in Immunotherapy of B Cell Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 2512-2512.	1.4	0
186	Chronic Lymphocytic Leukemia Cells May Become Less Dependent on Nurse-Like Cells during Later Stages of Disease.. Blood, 2004, 104, 4805-4805.	1.4	0
187	Increased Expression Level of Noxa in Peripheral Versus Lymph Node Chronic Lymphocytic Leukemia Cells Is Correlated with Survival Capacity.. Blood, 2006, 108, 4972-4972.	1.4	0
188	In Vivo Tumor Dynamic Studies in Stable CLL Show an Association between CLL Turnover Rates and IgVH Mutational Status and Provide Evidence That the Bone Marrow Is Not a Major Site of Neoplastic Cell Generation.. Blood, 2007, 110, 1128-1128.	1.4	0
189	CD31-CD38 Interaction Has No Major Role in the Pathogenesis of CLL.. Blood, 2007, 110, 1139-1139.	1.4	0
190	Platinum-Based Compounds Induce Expression of p73 and Restores Drug- Sensitivity in p53 Dysfunctional Chronic Lymphocytic Leukemia (CLL) Cells.. Blood, 2008, 112, 2102-2102.	1.4	0
191	R-DHAP Is Effective in Fludarabine-Refractory CLL, Possibly Via Upregulation of Pro-Apoptotic P73.. Blood, 2009, 114, 3449-3449.	1.4	0
192	ROS-Mediated Upregulation of Noxa Overcomes Drug-Resistance Due to P53-Dysfunction in Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 2382-2382.	1.4	0
193	Role of T Cell-Derived IL-21 in the Proliferation of Chronic Lymphocytic Leukemia Cells,. Blood, 2011, 118, 3871-3871.	1.4	0
194	R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 2883-2883.	1.4	0
195	CMV-Specific CD8+ T-CELL Function Is NOT Impaired In CLL. Blood, 2013, 122, 2862-2862.	1.4	0
196	Next-Generation Sequencing Reveals Oncogenic Driver Mutations In Both Progressive and Non-Progressive Monoclonal B Lymphocytosis. Blood, 2013, 122, 1615-1615.	1.4	0
197	Exome-Wide Sequencing Reveals Oncogenic Mutations in Both Progressive and Non-Progressive MBL. Blood, 2015, 126, 361-361.	1.4	0
198	Targeting BCR-Independent Proliferation of CLL Cells. Blood, 2015, 126, 2916-2916.	1.4	0

#	Article	IF	Citations
199	CLL Disease Severity Is Enhanced in Tcl1 Mice Deficient for Pro-Apoptotic Regulator Noxa. Blood, 2015, 126, 4144-4144.	1.4	0
200	B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide.. Journal of Clinical Oncology, 2018, 36, 7531-7531.	1.6	0
201	A New Therapeutic Hypothesis: Nonsense-Mediated Decay Is an Exploitable Target in Multiple Myeloma. Blood, 2018, 132, 1937-1937.	1.4	0
202	First Evidence of Dysfunctional Antigen-Specific T Cell Responses in Experimental CLL As a Model for Studies of Autologous T Cell-Based Therapies. Blood, 2018, 132, 3694-3694.	1.4	0
203	Cross-Talk between Cytokine and NF-Ä‚b Signaling in the CLL Microenvironment Can Affect Sensitivity for Venetoclax. Blood, 2019, 134, 5449-5449.	1.4	0
204	CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction. Blood, 2019, 134, 3043-3043.	1.4	0
205	Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.. Journal of Clinical Oncology, 2020, 38, e20011-e20011.	1.6	0
206	Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance. Blood, 2021, 138, 3717-3717.	1.4	0
207	Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2021, 138, 3721-3721.	1.4	0
208	For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation. Blood, 2021, 138, 754-754.	1.4	0
209	Bispecific Vî³9Vî´2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML. Blood, 2021, 138, 2266-2266.	1.4	0
210	Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax-Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial. Blood, 2021, 138, 1551-1551.	1.4	0
211	Development of a Novel Lymph Node-Based 3D Culture System Promoting Chronic Lymphocytic Leukemia Proliferation and Survival. Blood, 2020, 136, 47-48.	1.4	0
212	Electron Transport Chain Inhibition Suppresses CD40 Expression and Sensitizes Chronic Lymphocytic Leukaemia Cells to Venetoclax. Blood, 2020, 136, 35-35.	1.4	0